A challenge for maintaining immunotherapy responses in DLBCL is the presence of anti‐inflammatory cytokines, such as TGF‐β, interleukin‐10 (IL‐10), and vascular endothelial growth factor (VEGF), principally produced by tumor‐associated macrophages (TAMs), myeloid‐derived suppressor cells, and cancer‐associated fibroblasts.105, 107. This evidence concerns the gene VEGFA and diffuse large B-cell lymphoma.